Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors
Completed · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances such as radioactive iodine to them without harming normal cells. PURPOSE: This randomized phase I/II trial is studying the side effects, best way to give, and best dose of radiolabeled monoclonal antibody and to see how well it works in treating patients with primary brain tumors.
Key facts
- Study ID
- NCT00003478
- Run by
- Duke University
- People needed
- 10
- Starts
- 1997-10-01
- Expected to finish
- 2007-07-01
- Last updated by the study team
- 2013-02-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.